Investigation of nanostructured lipid carriers for transdermal delivery of flurbiprofen.
The aim of this study was to develop nanostructured lipid carriers (NLC) for transdermal delivery of Flurbiprofen (FP). The physical stability of FP-NLC and its in vitro permeation profile were investigated. After three months of storage at 4 degrees C, 20 degrees C, and 40 degrees C, no significant differences between the evaluated parameters, such as pH value, the entrapment efficiency, particle size, and zeta potential were observed. In in vitro permeation studies, the cumulative permeated amounts and the release rate from FP-NLC were 412.53 +/- 21.37 microg/cm(2) and 35.25 microg/cm(2)/h after 12 h (n = 6), respectively, while from saturated FP-PBS (pH = 7.4) were 90.83 +/- 8.67 microg/cm(2) and 6.99 microg/cm(2)/h, respectively. These results indicated that the FP-NLC were with good physical stability and were able to improve the permeated amounts and the release rate of FP. It could potentially be exploited as a carrier with improved drug entrapment efficiency and permeated amount in the transdermal delivery of FP.
Han
Fei
F
School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang, Liaoning Province, People's Republic of China.
Li
Sanming
S
Yin
Ran
R
Shi
Xiaolei
X
Jia
Qiang
Q
D000279:Administration, Cutaneous; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004337:Drug Carriers; D004355:Drug Stability; D004356:Drug Storage; D005480:Flurbiprofen / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D008055:Lipids; D008297:Male; D049329:Nanostructures; D010316:Particle Size; D051381:Rats; D017208:Rats, Wistar; D012869:Skin Absorption; D013696:Temperature
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004337:Drug Carriers; D008055:Lipids; D005480:Flurbiprofen